Table 1.
Demographics of patients with epithelioid glioblastoma
| Parameter | Parameter | ||
|---|---|---|---|
| Age (years) | Extent of resection (%) | ||
| Median age | 39 | GTR | 41(70.7%) |
| Range | 5–70 | STR | 8(13.8%) |
| Pre-operative KPS | PR | 9(15.5%) | |
| Median KPS | 80 | Stupp regimen (%) | 38(65.5%) |
| Range | 30–100 | Recurrence (%) | 39(67.2%) |
| Sex (%) | Local Recurrence | 30(51.7%) | |
| Male | 30(51.7%) | Distant Recurrence | 9(15.5%) |
| Female | 28(48.3%) | Recurrent KPS | |
| Presenting symptom (%) | Median KPS | 70 | |
| Headaches & dizziness | 42(72.4%) | Range | 50–90 |
| Limb weakness | 6(10.3%) | Treatment after recurrence (%) | |
| Epileptic | 6(10.3%) | Surgery & radiotherapy | 14(35.9%) |
| Diplopia | 1(1.7%) | Only Surgery | 4(10.3%) |
| Other | 3(5.2%) | Only radiotherapy | 5(12.8%) |
| Tumor location (%) | Supportive therapy | 16(41.0%) | |
| Temporal lobe | 21(36.2%) | Bevacizumab (%) | 10(17.2%) |
| Frontal lobe | 8(13.7%) | BRAF inhibitor (%) | 6(10.3%) |
| Parietal lobe | 5(8.6%) | State of survival (%) | |
| Other | 4(6.8%) | Censored | 23(39.7%) |
| Multiple lobes | 20(34.5%) | Mortality | 35(60.3%) |
| Tumor dissemination | 22(37.9%) | Median PFS (months) | 12.7 |
| Leptomeningeal dissemination | 17(29.3%) | Median OS (months) | 29.1 |
| CSF diffusion | 5(8.6%) | Median survival time after Recurrence (months) | 14.3 |
KPS Karnofsky Performance Scale, CSF Cerebrospinal Fluid, GTR Gross Total Resection, STR Subtotal Resection, PR Partial Resection, PFS Progression-free Survival, OS Overall Survival